Victoria Richon Net Worth

Victoria Richon biography

Dr. Victoria M. Richon Ph.D. serves as Independent Director of the Company. Dr. Richon has served as President and Chief Executive Officer of Ribon Therapeutics Inc., a biotechnology company, since November 2015. Prior to joining Ribon, Dr. Richon was Vice President, Global Head of Oncology Research and Translational Medicine at Sanofi Oncology from November 2012 to October 2015. Dr. Richon previously served as our Vice President of Biological Sciences from October 2008 to November 2012. Dr. Richon received her Ph.D. in biochemistry at the University of Nebraska Medical Center and a B.A. in chemistry at the University of Vermont.

What is the salary of Victoria Richon?

As the Independent Director of Epizyme Inc, the total compensation of Victoria Richon at Epizyme Inc is $308,559. There are 9 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.

How old is Victoria Richon?

Victoria Richon is 61, he's been the Independent Director of Epizyme Inc since 2019. There are 4 older and 14 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.

What's Victoria Richon's mailing address?

Victoria's mailing address filed with the SEC is C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Epizyme Inc

Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.

What does Epizyme Inc do?

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..

Epizyme Inc executives and stock owners

Epizyme Inc executives and other stock owners filed with the SEC include:

• Robert Bazemore,
  President, Chief Executive Officer, Director
• Shefali Agarwal,
  Chief Medical Officer
• Paolo Tombesi,
  Chief Financial Officer
• Matthew Ros,
  Chief Strategy and Business Officer
• Dr. Shefali Agarwal M.D., MPH,
  Exec. VP and Chief Medical & Devel. Officer
• Matthew E. Ros,
  Advisor
• Dr. Jeffery L. Kutok M.D., Ph.D.,
  Chief Scientific Officer
• Pablo Legorreta,
  Director
• Grant Bogle,
  Independent Director
• Victoria Richon,
  Independent Director
• David Mott,
  Independent Chairman of the Board
• Carl Goldfischer,
  Independent Director
• Kenneth Bate,
  Independent Director
• Andrew Allen,
  Independent Director
• Kevin Conroy,
  Independent Director
• Michael Giordano,
  Director
• Grant C. Bogle,
  Pres, CEO, Principal Financial Officer & Director
• Alicia Davis,
  IR Contact Officer
• Jeffery Kutok,
  Chief Scientific Officer
• Erin Boyer,
  Chief People & Culture Officer
• Craig West CFA,
  VP of Investor Relations
• John F. Weidenbruch,
  Sr. VP, Gen. Counsel & Sec.
• Jason Fredette,
  VP of Investor Relations
• Dr. Jeffery L. Kutok,
  Chief Scientific Officer
• Joseph Beaulieu,
  Controller, Treasurer & Principal Accounting Officer
• Dr. Yi Zhang,
  Scientific Co-Founder & Member of The Scientific Advisory Board
• Dr. H. Robert Horvitz,
  Co-Founder & Chairman of the Scientific Advisory Board
• Robert A Copeland,
  EVP and CSO
• Richard F Pops,
  Director
• Susan E Graf,
  Chief Business Officer
• Peter Tai Ching Ho,
  Chief Development Officer
• Pablo G.Rp Management, Llcr...,
  
• Beth C Seidenberg,
  Director
• Joseph Beaulieu,
  See Remarks
• Suzanne Fleming,
  SVP
• M James Barrett,
  10% owner
• Ryan D Drant,
  10% owner
• Xiii Associates, Llckleiner...,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Perkins Caufield & Byers Xi...,
  
• Patrick J Kerins,
  10% owner
• City Capital Llc Bay City C...,
  
• Scott D Sandell,
  10% owner
• European Investment Co Llcc...,
  
• Robert J Gould,
  President and CEO
• Venture Fund I L.P.Astellas...,
  
• Stephen Garbacz,
  Principal Accounting Officer
• Ventures Llcamgen Inc Amgen,
  
• City Capital Llc Bay City C...,
  
• Lukegadicke Ansbert Evnin,
  
• Harry R Weller,
  10% owner
• Ravi Viswanathan,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter J Barris,
  10% owner
• Forest Baskett,
  10% owner
• Enterprise Associates 13 Lp...,
  10% owner
• Kazumi Shiosaki,
  Director
• Jason P Rhodes,
  President, CFO and Treasurer
• Enterprise Associates 13 Lp...,
  
• City Capital Llc Bay City C...,
  
• Eric Hedrick,
  Chief Medical Officer
• Partners 13, Limited Partne...,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Victoria Vakiener,
  Chief Commercial Officer
• Jerald Korn,
  Chief Operating Officer
• Carol Stuckley,
  Director
• Roy A Beveridge,,
  Director
• Pablo G.Rp Management, Llcr...,